FIELD: biotechnology.
SUBSTANCE: peptide made from 5 CTL epitopes of cancer antigens linked through amino acid linkers is obtained. The resulting peptide is used to stimulate peripheral blood lymphocytes in order to obtain a combination of CTL specific for the cancer antigen.
EFFECT: invention provides a peptide vaccine for cancer treatment for wide range of cancer patients without the need for HLA typing and regardless of patients' HLA types.
6 cl, 2 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PEPTIDE WITH 4 LINKED CTL-EPITHOPES | 2014 |
|
RU2636549C1 |
| EMULSIFIER COMPOSITION AND USE THEREOF | 2019 |
|
RU2793862C2 |
| ANTITUMOR AGENT AND A METHOD OF ITS EVALUATION | 2019 |
|
RU2803148C2 |
| FELAMENTOUS FUNGI CELL WITH PROTEASE DEFICIT AND METHODS OF ITS APPLICATION | 2013 |
|
RU2645252C2 |
| METHOD FOR ENZYMATIC REMOVAL OF BIOFILM, COMPOSITION AND SET | 2008 |
|
RU2495098C2 |
| PEPTIDE CANCER VACCINES EXPRESSING TUMOUR-SPECIFIC ANTIGENS | 2008 |
|
RU2464275C2 |
| CONJUGATE VACCINE ON BASIS OF ANTIGEN WT1 PEPTIDE | 2014 |
|
RU2668560C2 |
| CELLULAR VAMP CLEAVAGE ASSAY | 2017 |
|
RU2807994C2 |
| MYBL2 EPITOPE PEPTIDES AND VACCINES CONTAINING THEM | 2009 |
|
RU2496787C2 |
| TTK PEPTIDES AND VACCINES CONTAINING THEM | 2010 |
|
RU2531348C2 |
